← Back to search
PATTERN BIOSCIENCE, INC.
AUSTIN, TX, 78759
Unclaimed
Small Business
Prime contracting experience
1 record from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | VERIFICATION, CLINICAL EVALUATION, AND FDA CLEARANCE OF THE WORLD'S FIRST CULTURE-FREE PHENOTYPIC ID/AST DIAGNOSTIC PLATFORM | — | $22,500,000 | Mar 31, 2026 | Sep 26, 2024 – Jan 31, 2029 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Subcontracting experience
1 record from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | PATTERN IS DEVELOPING A SINGLE CELL ANALYSIS PLATFORM THAT ENABLES FAST, TARGETED ANTIBIOTIC TREATMENT BY DELIVERING RAPID PATHOGEN IDENTIFICATION (ID) AND PHENOTYPIC ANTIMICROBIAL SUSCEPTIBILITY TEST (AST) RESULTS. WE ACCOMPLISH ID AND AST USING A NOVEL METHOD THAT REDUCES SYSTEM COMPLEXITY, ENABLES COST-EFFECTIVE TESTING, AND PERMITS TESTING DIRECTLY FROM CHALLENGING NON-STERILE SPECIMENS. THE PATTERN PLATFORM UTILIZES PHENOTYPIC SUSCEPTIBILITY TESTING METHODS, ENSURING THE CLINICAL VALIDITY OF CURRENT GOLD STANDARD AST METHODS IS MAINTAINED FOR RAPID TESTING.
CONVENTIONAL ANTIBIOTIC SUSCEPTIBILITY TESTING TIMES OFTEN EXCEED 48 HOURS, WHICH LEAVES CLINICIANS WITH INCOMPLETE INFORMATION TO PROVIDE DEFINITIVE TREATMENT. AS A RESULT, CLINICIANS MUST TREAT EMPIRICALLY. WHEN CHOOSING AN EMPIRIC ANTIMICROBIAL REGIMEN, THE CLINICIAN MUST BALANCE THE RISK OF POOR PATIENT OUTCOME (FROM POTENTIALLY UNDER-TREATING A DRUG-RESISTANT PATHOGEN) AGAINST THE SOCIETAL VALUE OF ANTIMICROBIAL STEWARDSHIP. RAPID ID/AST CAN DRAMATICALLY SHORTEN THE EMPIRIC TREATMENT TIME WINDOW, ENABLING EARLIER THERAPEUTIC OPTIMIZATION THAT WILL IMPROVE PATIENT OUTCOMES AND HELP PRESERVE THE EFFICACY OF OUR MOST POTENT ANTIBIOTICS. 4500004486 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $62,427 | Dec 6, 2022 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced